Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Paulus Kirchhof: Left Atrial Appendage Occlusion vs DOACs
Nov 21, 2026, 12:44

Paulus Kirchhof: Left Atrial Appendage Occlusion vs DOACs

Paulus Kirchhof, Professor of Medicine (Cardiology) and Director of the Department of Cardiology at the University Medical Center Hamburg-Eppendorf, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of the American College of Cardiology (JACC), adding:

“Do left atrial appendage occluders reduce major bleeding events compared to DOACs?

You may think ‘yes of course’, but the reality is more nuanced when you put that hypothesis to the test in controlled clinical trials. Find out more in a recently published individual patient data meta analysis of the CLOSURE-AF and PRAGUE-17 trials.

These signals illustrate the power of investigator-initiated research. Time to reconsider and refine management strategies. And time to thank the public funders, including the German Government, for their support for this important type of research.”

Title: Left Atrial Appendage Closure in Atrial Fibrillation Patients With High Risk of Stroke and Bleeding: An Individual Participant Data Meta-Analysis of Randomized Trials

Authors: Carsten Skurk, Ingo Eitel, Tharusan Thevathasan, Petr Neuzil, Paulus Kirchhof, Holger Thiele, Marcus Sandri, Andreas Zeiher, David Leistner, Andreas Rillig, Manuela Licka, Norbert Frey, Jörg Hausleiter, Steffen Massberg, Erlon Xhepa, Karl Georg Haeusler, Matthias Endres, Miriam Puls, Klara Benesova, Tim Friede, Karl Wegscheider, Leif-Hendrik Boldt, Vivek Y. Reddy, Pavel Osmancik, Ulf Landmesser

Paulus Kirchhof: Left Atrial Appendage Occlusion vs DOACs

Other posts featuring Paulus Kirchhof on Hemostasis Today.